Last reviewed · How we verify
UMEC
UmeC is a small molecule drug that works by interacting with a specific target in the body.
UmeC is a small molecule drug developed by Glaxo Group in England, currently owned by the same company. Unfortunately, there is limited information available on its target, drug class, or approved indications. As a result, its mechanism of action, safety considerations, and commercial status are unknown. Further research is needed to understand the potential benefits and risks of UmeC. Its status as a patented or generic medication also remains unclear.
At a glance
| Generic name | UMEC |
|---|---|
| Sponsor | Glaxo Grp England |
| Target | Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Imagine UmeC as a key that fits into a lock in the body. When it binds to this lock, it triggers a series of events that can help to treat a particular condition. However, without more information, it's difficult to say exactly how UmeC works or what condition it's intended to treat.
Approved indications
- Asthma
- Chronic bronchitis
- Chronic obstructive lung disease
- Pulmonary emphysema
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Cough
- Arthralgia
- Pharyngitis
- Viral upper respiratory tract infection
- Myalgia
- Abdominal pain upper
- Toothache
- Contusion
- Tachycardia
Serious adverse events
- Atrial fibrillation
- Pneumonia
- Supraventricular tachycardia
- Supraventricular extrasystoles
- Sinus tachycardia
- Idioventricular rhythm
- Depression
Key clinical trials
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
- Evaluation of Supraclavicular Brachial Plexus Blocks at Various Volumes: Impact on Optic Nerve Sheath Diameter (NA)
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD (PHASE4)
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma (PHASE3)
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (PHASE4)
- Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma (PHASE3)
- Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UMEC CI brief — competitive landscape report
- UMEC updates RSS · CI watch RSS
- Glaxo Grp England portfolio CI